Abstracts tagged "Systemic JIA and tocilizumab"

Abstract Number: 1413 • 2018 ACR/ARHP Annual Meeting
Safety of Tocilizumab in Patients Aged <2 Years with Active Systemic Juvenile Idiopathic Arthritis Treated for One Year
Sunethra Wimalasundera¹, Inmaculada Calvo², Rubén J. Cuttica³, Hans-Iko Huppertz⁴, Rik Joos⁵, Diana Milojevic⁶, Margalit Rosenkranz⁷, Kenneth Schikler⁸, Tamás Constantin⁹, Wendy Douglass¹, Chris Wells¹, Yukiko Kimura¹⁰ and Carine Wouters¹¹, ¹Roche Products Ltd., Welwyn Garden City, United Kingdom, ²Hospital Universitario La Fe, Valencia, Spain, ³Hospital General de Niños Pedro de Elizalde, Buenes Aires, Argentina, ⁴Professor Hess Children's Hospital, Bremen, Germany, ⁵ZNA, Antwerp, and UZ, Gent, Belgium, ⁶Tufts Medical Center, Boston, MA, ⁷Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ⁸University of Louisville Medical School, Louisville, KY, ⁹Semmelweis University, Budapest, Hungary, ¹⁰Hackensack University Medical Center, Hackensack, NJ, ¹¹University Hospital Gasthuisberg, Leuven, Belgium
Background/Purpose: The US Food and Drug Administration approved intravenous (IV) tocilizumab (TCZ) for patients (pts) ≥2 years of age with systemic JIA (sJIA) in 2011…
Abstract Number: 2379 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Subcutaneous Tocilizumab Administration in Systemic and Polyarticular Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicola Ruperto², Alberto Martini², Athimalaipet V. Ramanan³, Rubén J. Cuttica⁴, Jennifer E. Weiss⁵, Michael Henrickson¹, Heinrike Schmeling⁶, Jordi Anton⁷, Kirsten Minden⁸, Gerd Horneff⁹, María Luz Gámir-Gámir¹⁰, Markus Hufnagel¹¹, Wendy Douglass¹², Chris Wells¹², Sunethra Wimalasundera¹², Navita L. Mallalieu¹³, Daniel J Lovell¹ and Fabrizio De Benedetti¹⁴, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology International Trial Organization (PRINTO) Coordinating Centre, Genoa, Italy, ³Bristol Royal Hospital for Children, Bristol, United Kingdom, ⁴Hospital Gral de Niños Pedro Elizalde, Buenos Aires, Argentina, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶Alberta Children’s Hospital/University of Calgary, Calgary, AB, Canada, ⁷Hospital Sant Joan de Deu, Barcelona, Spain, ⁸Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁹Asklepios Clinic Sankt Augustin, and University Hospital of Cologne, Cologne, Germany, ¹⁰Hospital Ramon y Cajal Unidad de Reumatologia Pediatrica, Madrid, Spain, ¹¹Department of Pediatrics and Adolescent Medicine, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom, ¹³Roche Innovation Center, New York, NY, ¹⁴IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: Tocilizumab (TCZ) administered intravenously (IV) was shown to improve the signs and symptoms of polyarticular (p)JIA and systemic (s)JIA.1,2 An ongoing 3-year, long-term extension…
Abstract Number: 43 • 2017 Pediatric Rheumatology Symposium
Tocilizumab Use in Pediatrics With Systemic Juvenile Idiopathic Arthritis: Single Center Data
Swati Jain¹, M. Brooke Bernhardt¹, Andrea A. Ramirez², Anna Carmela Sagcal-Gironella³ and Marietta de Guzman⁴, ¹Pharmacy, Texas Children's Hospital, Houston, TX, ²Pediatric Rheumatology, Texas Children's Hospital, Houston, TX, ³Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Tocilizumab is a humanized monoclonal antibody against interleukin-6 receptors and is indicated for the treatment of systemic juvenile idiopathic arthritis (sJIA) in patients 2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].